EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Contemporary Medical Therapy for Heart Failure Across the Ejection Fraction Spectrum: The OPTIPHARM-HF Registry

Zeitgemäße medikamentöse Therapie bei Herzinsuffizienz über das gesamte Ejektionsfraktionsspektrum: das OPTIPHARM-HF-Register

Riccardo M Inciardi, Maurizio Volterrani, Gianluigi Savarese, Muthiah Vaduganathan, Chiara Oriecuia, Carlo M Lombardi, Cristina Gussago, Piergiuseppe Agostoni, Pietro Ameri, Giuseppe Armentaro, Chiara Arzilli, Nadia Aspromonte und 48 weitere

European Journal of Heart Failure · 01.12.2025 · 27 (12) · 2691-2704

DOI: 10.1002/ejhf.70074 ↗

Auf einen Blick

Im OPTIPHARM-HF-Register war die leitliniengerechte medikamentöse Therapie bei Herzinsuffizienz über alle EF-Bereiche unzureichend. Nach dem Erstbesuch nahm die Verordnung mehrerer Substanzklassen zu.

Fragestellung

Wie häufig werden GDMT, Dosierung und Umsetzung bei Herzinsuffizienz über das gesamte Ejektionsfraktionsspektrum in einer aktuellen landesweiten Kohorte eingesetzt?

Methode

Prospektive, multizentrische, beobachtende Studie in 32 italienischen HF-Zentren; Erwachsene mit HF und HFrEF, HFmrEF oder HFpEF wurden von September 2022 bis Dezember 2024 eingeschlossen.

Ergebnisse

3054 Patient:innen; 56 % HFrEF, 21 % HFmrEF, 23 % HFpEF. Bei HFrEF: Beta-Blocker 90 %, ACEi/ARB 19 %, ARNI 61 %, MRA 72 %, SGLT2i 69 %; <60 % erreichten ≥50 % der Zieldosis. Quadruple Therapie 47 %, nach Erstbesuch 64 % (p < 0,001).

Schlussfolgerung der Autor:innen

Der Einsatz von GDMT blieb über das EF-Spektrum suboptimal, obwohl die Einführung der quadruple GDMT bei HFrEF und von SGLT2i bei HFmrEF und HFpEF in den letzten Jahren zunahm.

Kernaussagen

  • GDMT bei Herzinsuffizienz blieb insgesamt unterhalb der Leitlinienziele
  • Bei HFrEF erhielten 47 % eine quadruple Therapie
  • SGLT2i-Verordnungen stiegen nach dem Erstbesuch bei HFmrEF und HFpEF

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Heart Failure, online erschienen am 17.12.2025. Verfasst von Riccardo M Inciardi und 59 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of…. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Registries. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Despite guideline recommendations, guideline-directed medical therapy (GDMT) remains underused and underdosed in patients with heart failure (HF) across the ejection fraction (EF) spectrum. The aim of this study was to evaluate GDMT use, dosing, and implementation in a contemporary, nationwide HF cohort. Methods and results The OPTIPHARM-HF (NCT06192524) is a prospective, multicentre, observational study enrolling adult patients with HF, across 32 Italian HF centres. Clinical characteristics, medical therapy prevalence and change after first visit have been assessed in patients with reduced (HFrEF: EF ≤40%), mildly reduced (HFmrEF: EF 40–49%), and preserved EF (HFpEF: EF ≥50%). From September 2022 to December 2024, 3054 patients (mean age 69 ± 12 years, 25% female) were enrolled: 56% with HFrEF, 21% with HFmrEF, and 23% with HFpEF. Among HFrEF, prescription frequencies were: 90% for beta-blockers; 19% for angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB); 61% for angiotensin receptor–neprilysin inhibitors (ARNI); 72% for mineralocorticoid receptor antagonists (MRA); and 69% for sodium–glucose co-transporter 2 inhibitors (SGLT2i). Less than 60% achieved ≥50% of target doses. Quadruple therapy was received by 47% of the patients. After first visit, there was an increase in prescription of all classes of drugs, and titration to quadruple therapy was attained in 64% (p < 0.001). Among HFmrEF, 88% were on beta-blockers, 34% on ACEi/ARB, 49% on ARNI, 63% on MRA, and 59% on SGLT2i. In the HFpEF group, 76% were on beta-blockers, 49% on ACEi/ARB, 18% on ARNI, 49% on MRA and 40% on SGLT2i. After the first visit, SGLT2i prescription significantly increased both in HFmrEF (74%, p < 0.001) and HFpEF (54%, p < 0.001).

Conclusions

Use of GDMT remains suboptimal across the EF spectrum although the adoption of quadruple GDMT in HFrEF and of SGLT2i in HFmrEF and HFpEF increased in recent years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeRegistriesHumansFemaleMaleAgedProspective StudiesAngiotensin-Converting Enzyme InhibitorsAdrenergic beta-AntagonistsMineralocorticoid Receptor AntagonistsMiddle AgedAngiotensin Receptor AntagonistsItalySodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

Ejection fraction spectrumHeart failureMedical therapyOptimizationRegistry

Substanzen

Angiotensin-Converting Enzyme InhibitorsAdrenergic beta-AntagonistsMineralocorticoid Receptor AntagonistsAngiotensin Receptor AntagonistsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
  • Division of Cardiology, Department of Clinical Science and Education, Center for Heart Failure and Arrhythmia, Karolinska University Hospital, Stockholm, Sweden.
  • Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Exercise Science and Medicine, San Raffaele Open University of Rome, Italy, and Cardiopulmonary Department, RCCS San Raffaele Roma, Rome, Italy.
  • Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
  • Centro Cardiologico Monzino, IRCCS, Department of Clinical Sciences and Community Health, Milan, Italy.

Zitieren

APA

Inciardi, R. M., Volterrani, M., Savarese, G., Vaduganathan, M., Oriecuia, C., Lombardi, C. M., Gussago, C., Agostoni, P., Ameri, P., Armentaro, G., Arzilli, C., Aspromonte, N., Attanasio, A., Badagliacca, R., Barbieri, L., Bocchino, P. P., Bursi, F., Cameli, M., Canonero, M., …, & Pinto, G. (2025). Contemporary Medical Therapy for Heart Failure Across the Ejection Fraction Spectrum: The OPTIPHARM-HF Registry. European Journal of Heart Failure, 27(12), 2691-2704. https://doi.org/10.1002/ejhf.70074

Vancouver

Inciardi RM, Volterrani M, Savarese G, Vaduganathan M, Oriecuia C, Lombardi CM, et al. Contemporary Medical Therapy for Heart Failure Across the Ejection Fraction Spectrum: The OPTIPHARM-HF Registry. European Journal of Heart Failure. 2025;27(12):2691-2704. doi:10.1002/ejhf.70074

BibTeX
@article{Inciardi2025,
  author = {Inciardi, Riccardo M and Volterrani, Maurizio and Savarese, Gianluigi and Vaduganathan, Muthiah and Oriecuia, Chiara and Lombardi, Carlo M and Gussago, Cristina and Agostoni, Piergiuseppe and Ameri, Pietro and Armentaro, Giuseppe and Arzilli, Chiara and Aspromonte, Nadia and Attanasio, Andrea and Badagliacca, Roberto and Barbieri, Lucia and Bocchino, Pier Paolo and Bursi, Francesca and Cameli, Matteo and Canonero, Martino and Campodonico, Jeness S and Capovilla, Teresa and Carluccio, Erberto and Carugo, Stefano and Castiglione, Vincenzo and Catapano, Dario and Cipriani, Manlio and Correale, Michele and D'Amario, Domenico and De Caterina, Raffaele and De Ferrari, Gaetano M and D'Elia, Emilia and Di Odoardo, Luca and Emdin, Michele and Falco, Luigi and Ferrante, Giulia and Fornaro, Alessandra and Fornaro, Paolo and Guastamiglio, Gionata and Guazzi, Marco and Iacoviello, Massimo and Imazio, Massimo and Incaminato, Enrico and La Rovere, Maria Teresa and Leonardi, Sergio and Maccallini, Marta and Mandoli, Giulia E and Masarone, Daniele and Masetti, Marco and Mazzoni, Alberto and Mazzotta, Marta and Merlo, Marco and Moschini, Luigi and Novarese, Filippo and Palazzuoli, Alberto and Pastore, Maria C and Patti, Giuseppe and Pedretti, Roberto F E and Pidello, Stefano and Piepoli, Massimo F and Pinto, Giuseppe},
  title = {Contemporary Medical Therapy for Heart Failure Across the Ejection Fraction Spectrum: The OPTIPHARM-HF Registry},
  journal = {European Journal of Heart Failure},
  year = {2025},
  volume = {27},
  number = {12},
  pages = {2691--2704},
  doi = {10.1002/ejhf.70074}
}
Kostenlos starten →